Related Experiment Video
Updated: Sep 30, 2025
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.7K
Formyl peptide receptor 2 and heart disease
John A Lupisella1, Pravin S Shirude2, Nicholas R Wurtz1
1Department of Cardiovascular and Fibrosis Drug Discovery, Bristol Myers Squibb, Princeton, NJ, USA.
Seminars in Immunology
|March 12, 2022
Summary
Formyl peptide receptor type 2 (FPR2) plays a key role in managing inflammation after heart injury. Activating FPR2 may improve heart function by promoting healing and reducing disease progression.
Area of Science:
- Cardiovascular Research
- Immunology
- Pharmacology
Background:
- Formyl peptide receptor type 2 (FPR2) is crucial for regulating inflammatory responses.
- Dysregulated inflammation following heart injury can lead to adverse cardiac remodeling and dysfunction.
- Targeting inflammation resolution is a potential therapeutic strategy for heart disease.
Purpose of the Study:
- To review the emerging role of FPR2 in heart disease.
- To explore strategies for activating pro-resolution processes via FPR2.
- To summarize preclinical and clinical evidence for FPR2 agonists in cardiac conditions.
Main Methods:
- Literature review of preclinical studies on FPR2 in heart disease models.
- Analysis of emerging concepts in inflammation resolution.
- Summary of clinical trial status for FPR2 agonists.
Main Results:
- FPR2 activation is linked to regulating both the initiation and resolution of inflammation.
- Preclinical data suggest FPR2 agonists can mitigate maladaptive healing and pathological remodeling in the heart.
- Evidence supports the potential of FPR2 modulation to improve outcomes in heart disease.
Conclusions:
- FPR2 is a significant regulator of cardiac inflammation and healing.
- Targeting FPR2 with agonists offers a promising therapeutic avenue for heart disease.
- Further clinical evaluation of FPR2 agonists is warranted to confirm their efficacy and safety.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.0K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.0K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
244
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
244
01:29Heart Failure II: Pathophysiology
82
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
82
01:30Transducer Mechanism: G Protein–Coupled Receptors
2.7K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.7K
01:26Coronary Artery Disease II: Pathophysiology
69
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
69
01:23Rheumatic Heart Disease I: Introduction
69
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
69